Literature DB >> 23055895

Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review.

Kim W Benner1, Mary A Worthington, David W Kimberlin, Kim Hill, Kevin Buckley, Nancy M Tofil.   

Abstract

OBJECTIVES: Appropriate antimicrobial dosing maximizes therapeutic benefit while minimizing development of antimicrobial resistance. Common pediatric references recommend vancomycin dosing of 40 mg/kg/day divided every 6 to 8 hours for non-central nervous system infections, while some clinicians report utilizing higher initial doses to optimize efficacy. This study compares vancomycin serum concentrations following traditional dosing of 10 mg/kg/dose every 6 to 8 hours versus 15 to 20 mg/kg/dose every 6 to 8 hours. STUDY
DESIGN: Retrospective database review of vancomycin serum concentrations in pediatric patients.
RESULTS: Three hundred fifty-seven patients were analyzed. The mean peak concentration of the 10 mg/kg groups every 6 and every 8 hours were below 25 mg/L, whereas the mean peak concentrations of the 15 mg/ kg groups every 6 and 8 hours were within the 25-40 mg/L range (p < 0.001). The mean trough concentration of the 10 mg/kg group every 6 hours was within the 5-15 mg/L range while the 10 mg/kg group dosed every 8 hours was below target. However, the mean trough concentrations of the 15 mg/kg group dosed every 6 and 8 hours were both within the 5-15 mg/L range (p < 0.001).
CONCLUSIONS: Vancomycin doses of 15 mg/kg every 6 to 8 hours produce peak and trough serum concentrations within target range more often than 10 mg/kg every 6 to 8 hours.

Entities:  

Keywords:  pediatrics; pharmacokinetics; vancomycin dosing; vancomycin serum concentrations

Year:  2009        PMID: 23055895      PMCID: PMC3461982          DOI: 10.5863/1551-6776-14.2.86

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  30 in total

Review 1.  Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.

Authors:  K A Rodvold; J A Everett; R D Pryka; D M Kraus
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Why monitor peak vancomycin concentrations?

Authors:  N J Saunders
Journal:  Lancet       Date:  1994 Dec 24-31       Impact factor: 79.321

3.  The influences of renal function and maturation on vancomycin elimination in newborns and infants.

Authors:  E V Capparelli; J R Lane; G L Romanowski; E J McFeely; W Murray; P Sousa; C Kildoo; J D Connor
Journal:  J Clin Pharmacol       Date:  2001-09       Impact factor: 3.126

4.  Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function.

Authors:  M L Glover; E Cole; J Wolfsdorf
Journal:  J Crit Care       Date:  2000-03       Impact factor: 3.425

5.  Nephrotoxicity of vancomycin, alone and with an aminoglycoside.

Authors:  M J Rybak; L M Albrecht; S C Boike; P H Chandrasekar
Journal:  J Antimicrob Chemother       Date:  1990-04       Impact factor: 5.790

6.  Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice.

Authors:  L S Elting; E B Rubenstein; D Kurtin; K V Rolston; J Fangtang; C G Martin; I I Raad; E E Whimbey; E Manzullo; G P Bodey
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

7.  Vancomycin use in hospitalized pediatric patients.

Authors:  Harry L Keyserling; Ronda L Sinkowitz-Cochran; James M Harris; Gail L Levine; Jane D Siegel; Beth H Stover; Sharon A Lau; William R Jarvis
Journal:  Pediatrics       Date:  2003-08       Impact factor: 7.124

8.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

9.  A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients.

Authors:  D Chang; L Liem; M Malogolowkin
Journal:  Pediatr Infect Dis J       Date:  1994-11       Impact factor: 2.129

10.  Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.

Authors:  M E Klepser; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Pharmacotherapy       Date:  1998 Sep-Oct       Impact factor: 4.705

View more
  11 in total

Review 1.  Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.

Authors:  Geisa Cristina da Silva Alves; Samuel Dutra da Silva; Virginia Paula Frade; Danielle Rodrigues; André de Oliveira Baldoni; Whocely Victor de Castro; Cristina Sanches
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

2.  Pediatric Assessment of Vancomycin Empiric Dosing (PAVED): a Retrospective Review.

Authors:  Daniel Rainkie; Mary H H Ensom; Roxane Carr
Journal:  Paediatr Drugs       Date:  2015-06       Impact factor: 3.022

3.  Vancomycin dosage regimens for pediatric patients.

Authors:  Milap C Nahata
Journal:  J Pediatr Pharmacol Ther       Date:  2009-04

Review 4.  Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin.

Authors:  Roopali Sharma; Margaret R Hammerschlag
Journal:  Curr Infect Dis Rep       Date:  2019-09-05       Impact factor: 3.725

5.  Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.

Authors:  Whitney R Buckel; Shahira Ghobrial; Pranita D Tamma; Aaron M Milstone; Yuan Zhao; Alice J Hsu
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

6.  Achieving therapeutic vancomycin levels in pediatric patients.

Authors:  Jenny Hoang; Deonne Dersch-Mills; Lauren Bresee; Timothy Kraft; Otto G Vanderkooi
Journal:  Can J Hosp Pharm       Date:  2014-11

7.  Vancomycin dosing in healthy-weight, overweight, and obese pediatric patients.

Authors:  Lea S Eiland; Kalyani B Sonawane
Journal:  J Pediatr Pharmacol Ther       Date:  2014-07

8.  An evaluation of initial vancomycin dosing in infants, children, and adolescents.

Authors:  Laura Broome; Tsz-Yin So
Journal:  Int J Pediatr       Date:  2011-10-23

9.  Vancomycin use, dosing and serum trough concentrations in the pediatric population: a retrospective institutional review.

Authors:  Kevin Rajon; Regis Vaillancourt; Nisha Varughese; Gilda Villarreal
Journal:  Pharm Pract (Granada)       Date:  2017-06-30

10.  Successfully treated infective endocarditis caused by methicillin-resistant Staphylococcus Aureus in extremely low birth weight infant.

Authors:  Sehwa Jung; Kyung Uk Jeong; Jang Hoon Lee; Jo Won Jung; Moon Sung Park
Journal:  Korean J Pediatr       Date:  2016-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.